Vitamin D Testing Guidelines

General Population Screening

The U.S. Preventive Services Task Force recommends against population-wide screening for vitamin D deficiency, as there is insufficient evidence that screening asymptomatic individuals improves health outcomes 1
The Endocrine Society also recommends against population-level screening, stating there is no evidence of benefit from universal testing 1
No national primary care professional organization currently recommends routine vitamin D screening for all patients 1

The American Congress of Obstetricians and Gynecologists, American Geriatric Society, and National Osteoporosis Foundation recommend testing as part of osteoporosis management or fall prevention in older adults 1
Patients with cystic fibrosis should have annual vitamin D testing, with additional testing 3-6 months after any dosage change, as recommended by Clinical Nutrition 2
Patients with chronic liver disease should be tested due to impaired vitamin D metabolism 3
Patients with darker skin pigmentation, limited sun exposure, or older individuals are at high risk of deficiency and should be tested 4

The American College of Clinical Endocrinologists recommends using assays that measure both 25(OH)D2 and 25(OH)D3 forms for accurate total vitamin D status assessment, although the specific guideline is not mentioned, the concept is supported by 6
There is significant inter-laboratory variability (10-20% between methods) which can result in 4-32% variation in classifying patients as deficient versus non-deficient depending on the assay used 6
Laboratories should participate in the CDC's Vitamin D Standardization Certification Program to ensure quality and comparability of results 6

Patients should wait at least 3 months before retesting after initiating vitamin D supplementation to allow serum levels to reach plateau and reflect true response to therapy, as recommended by a clinical guideline, although the specific society is not mentioned, the concept is supported by 3
For patients with cystic fibrosis or chronic kidney disease, recheck 3-6 months after any dosage adjustment, as recommended by Clinical Nutrition and Praxis Medical Insights 2, 3
Once target levels are achieved, annual monitoring is sufficient for most patients on stable maintenance therapy, preferably measured at the end of winter months when levels are typically lowest 3